These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19713220)

  • 21. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.
    Bai LY; Omar HA; Chiu CF; Chi ZP; Hu JL; Weng JR
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):489-96. PubMed ID: 21072520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma.
    Khong T; Sharkey J; Spencer A
    Haematologica; 2008 Jun; 93(6):860-9. PubMed ID: 18443271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Panobinostat for the Treatment of Multiple Myeloma.
    Laubach JP; Moreau P; San-Miguel JF; Richardson PG
    Clin Cancer Res; 2015 Nov; 21(21):4767-73. PubMed ID: 26362997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-19b and miR-20a suppress apoptosis, promote proliferation and induce tumorigenicity of multiple myeloma cells by targeting PTEN.
    Yuan J; Su Z; Gu W; Shen X; Zhao Q; Shi L; Jin C; Wang X; Cong H; Ju S
    Cancer Biomark; 2019; 24(3):279-289. PubMed ID: 30883341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polycomb target genes are silenced in multiple myeloma.
    Kalushkova A; Fryknäs M; Lemaire M; Fristedt C; Agarwal P; Eriksson M; Deleu S; Atadja P; Osterborg A; Nilsson K; Vanderkerken K; Oberg F; Jernberg-Wiklund H
    PLoS One; 2010 Jul; 5(7):e11483. PubMed ID: 20634887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory T cells.
    Oberg HH; Wesch D; Grüssel S; Rose-John S; Kabelitz D
    Int Immunol; 2006 Apr; 18(4):555-63. PubMed ID: 16540526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.
    Chauhan D; Auclair D; Robinson EK; Hideshima T; Li G; Podar K; Gupta D; Richardson P; Schlossman RL; Krett N; Chen LB; Munshi NC; Anderson KC
    Oncogene; 2002 Feb; 21(9):1346-58. PubMed ID: 11857078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence.
    Cho JH; Dimri M; Dimri GP
    J Biol Chem; 2015 Apr; 290(16):10555-67. PubMed ID: 25737447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
    Cheng T; Grasse L; Shah J; Chandra J
    Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Drozdkova DH; Gursky J; Minarik J; Überall I; Kolar Z; Trtkova KS
    Anticancer Res; 2020 Sep; 40(9):4979-4987. PubMed ID: 32878786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.
    Mazzio EA; Soliman KF
    Cancer Genomics Proteomics; 2017 Jan; 14(1):17-33. PubMed ID: 28031235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
    Guerini V; Barbui V; Spinelli O; Salvi A; Dellacasa C; Carobbio A; Introna M; Barbui T; Golay J; Rambaldi A
    Leukemia; 2008 Apr; 22(4):740-7. PubMed ID: 18079739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells.
    Feng M; Luo X; Gu C; Fei J
    J Drug Target; 2015 Jan; 23(1):59-66. PubMed ID: 25185784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long noncoding RNA UCA1 regulates proliferation and apoptosis in multiple myeloma by targeting miR-331-3p/IL6R axis for the activation of JAK2/STAT3 pathway.
    Li JL; Liu XL; Guo SF; Yang Y; Zhu YL; Li JZ
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9238-9250. PubMed ID: 31773675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo.
    Li S; Fossati G; Marchetti C; Modena D; Pozzi P; Reznikov LL; Moras ML; Azam T; Abbate A; Mascagni P; Dinarello CA
    J Biol Chem; 2015 Jan; 290(4):2368-78. PubMed ID: 25451941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Expression of MiRNA-19a in Cells of Multiple Myeloma Patients and Its Effect on the Characteristics of Myeloma Cells].
    Yue ZJ; Zhang XY; Zhao P; Chen YF; Yuan Y; Jing YY; Zhou YX; Wang XF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):464-469. PubMed ID: 29665917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.
    Abdi J; Rastgoo N; Chen Y; Chen GA; Chang H
    BMC Cancer; 2019 Oct; 19(1):975. PubMed ID: 31638931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma].
    Stegmann DA
    Med Monatsschr Pharm; 2016 Apr; 39(4):142-7. PubMed ID: 27209894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.
    Barbetti V; Gozzini A; Rovida E; Morandi A; Spinelli E; Fossati G; Mascagni P; Lübbert M; Dello Sbarba P; Santini V
    Oncogene; 2008 Mar; 27(12):1767-78. PubMed ID: 17891169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF.
    Zhang B; Ma L; Wei J; Hu J; Zhao Z; Wang Y; Chen Y; Zhao F
    Curr Cancer Drug Targets; 2016; 16(9):807-817. PubMed ID: 26845432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.